Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

3-V Biosciences (Menlo Park, CA) a preclinical-stage biopharmaceutical company focused on host-factor antivirals for chronic Hepatitis C infection, closed a $20M Series C financing. Participants include Kleiner Perkins Caufield & Byers and New Enterprise Associates.

3-V Biosciences (Menlo Park, CA) a preclinical-stage biopharmaceutical company focused on host-factor antivirals for chronic Hepatitis C infection, closed a $20M Series C financing. Participants include Kleiner Perkins Caufield & Byers and New Enterprise Associates.

Hookipa Biotech (Austria) a development-stage pharmaceutical company focused on prophylactic and therapeutic vaccines for viral diseases, closed $9.7M Series A financing. Participants include Sofinnova Partners and Forbion Capital Partners.

Chimerix (Durham, NC) a clinical-stage pharma company developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $45M Series F financing. Participants include Pappas Ventures, Morningside Group, Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Co., Frazier Healthcare Ventures and New Leaf Venture Partners.

ViroXis (San Antonio, TX) a development stage biopharmaceutical company focused on antiviral treatment of HPV associated skin warts, closed a $2.5M Series A financing. Participants include Texas Emerging Technology Fund.

Beech Tree Labs (Providence, RI) a clinical-stage antiviral company focused on influenza and herpes, closed a $7M Series B financing. Participants were not identified.

Tobira Therapeutics (Manalapan, NJ) a clinical-stage biopharmaceutical company focused on antivirals for HIV and inflammation, closed a $31M B financing. Participants include Novo Ventures, Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.

Visterra (Cambridge, MA) a development-stage company focused virus-glycan docking to derive products for the prevention, treatment and diagnosis of influenza and other infectious diseases, closed a $6M Series A financing. Participants include Flagship Ventures, Lux Capital and Polaris Venture Partners.

HemaQuest Pharmaceuticals (Newton, MA) a clinical-stage small molecule company focused on hemoglobin disorders such as sickle cell disease, beta thalassemia, and viral-associated disease such as HPV, EBV and HIV, closed a $12M Series B financing. Participants include Aberdare Ventures, De Novo Ventures, Forward Ventures and Lilly Ventures.

AiCuris (Germany) a clinical-stage biopharmaceutical company focused on resistance breaking antiviral and antibacterial therapeutics targeting Human Cytomegalovirus, Herpes simplex, HIV, Hepatitis B and C and multi-resistant bacteria, closed a $74.8M Series B financing. Participants include Santo Holding and Bayer Healthcare.

Chimerix (Durham, NC) a clinical-stage developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $16M Series E financing. Participants include Canaan Partners, Alta Partners, Sanderling Ventures and Asset Management Company.

3-V Biosciences (Palo Alto, CA) a preclinical-stage biopharma company focused on broad-spectrum antivirals for respiratory viral infections, closed a $30M Series B financing. Participants include New Enterprise Associates, The Column Group and Kleiner Perkins Caulfield & Byers.

Alios BioPharma (San Francisco, CA) a preclinical-stage small molecule and protein therapeutics company focused on viral disease via innate immune modulation, closed a $8M Series A financing bring the total round to $32M. Participants include SR One, Novo Ventures, Novartis Venture Fund and Roche Venture Fund.

« Previous Entries  Next Page »

to top of page...